<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02480114</url>
  </required_header>
  <id_info>
    <org_study_id>VICC HN 1541</org_study_id>
    <secondary_id>NCI-2015-00750</secondary_id>
    <secondary_id>VICC HN 1541</secondary_id>
    <secondary_id>P30CA068485</secondary_id>
    <nct_id>NCT02480114</nct_id>
  </id_info>
  <brief_title>Gabapentin Compared to Standard of Care in Preventing Mucositis in Patients With Stage III-IV Head and Neck Cancer Undergoing Primary or Adjuvant Chemoradiation Therapy</brief_title>
  <official_title>A Randomized Phase III Trial of Gabapentin Versus Standard of Care for Prevention and Treatment of Mucositis in Locally Advanced Head and Neck Cancer Patients Undergoing Primary or Adjuvant Chemoradiation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt-Ingram Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Vanderbilt-Ingram Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized phase III trial studies how well gabapentin plus standard of care work&#xD;
      compares to standard of care without Gabapentin in preventing inflammation of the mucous&#xD;
      membranes (mucositis) in patients with stage III-IV head and neck cancer that are undergoing&#xD;
      primary or subsequent (adjuvant) chemoradiation therapy. Radiation therapy to the head and&#xD;
      neck may cause a burn involving the inside of the mouth, throat, and nasal passages,&#xD;
      resulting in pain. Gabapentin may help prevent (or minimize) pain associated with&#xD;
      radiation-induced mucositis in patients with head and neck cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objectives:&#xD;
&#xD;
      - To determine whether gabapentin used as a preventive measure during chemoradiation can&#xD;
      reduce radiation-induced mucositis associated pain in head and neck cancer patients as&#xD;
      measured by: 1) pain scores on the Vanderbilt Head and Neck Symptom Survey (VHNSS version&#xD;
      2.), and 2) analgesic use.&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
        -  To assess the safety (grade 3 or 4 adverse events) and tolerability of using gabapentin&#xD;
           (discontinuation of drug due to side effects - yes or no)&#xD;
&#xD;
        -  To correlate pain severity with frequency and severity of general systemic symptoms.&#xD;
&#xD;
      Exploratory Objectives:&#xD;
&#xD;
      - To determine whether pain control is associated with weight loss (in pounds) and duration&#xD;
      of use of percutaneous endoscopic gastrostomy utilization (in days).&#xD;
&#xD;
      OUTLINE: Patients are randomized to 1 of 2 arms.&#xD;
&#xD;
      ARM I: Standard of Care (usual care) - Patients receive consisting of oral health measures,&#xD;
      oral rinsing, miracle mouthwash, nonsteroidal anti-inflammatories, and opioid analgesics.&#xD;
      Patients also undergo an education session at the beginning of chemoradiation treatment to&#xD;
      review foundations of oral care and pain management.&#xD;
&#xD;
      ARM II: Standard of Care plus Gabapentin - Patients receive standard of care and undergo an&#xD;
      education session as in Arm I. Patients also receive gabapentin orally (PO) three times a day&#xD;
      throughout chemoradiation treatment (approximately 5-7 weeks) and until mucositis resolves&#xD;
      and pain subsides.&#xD;
&#xD;
      After completion of study treatment, patients are followed up monthly for 3 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Actual">January 2020</completion_date>
  <primary_completion_date type="Actual">September 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Pain Associated With Radiation-induced Mucositis, (Pain Subscale of the Vanderbilt Head and Neck Symptom Survey (VHNSS))</measure>
    <time_frame>Up to 3 months post-treatment</time_frame>
    <description>The pain subscale is composed of 4 items of the Vanderbilt Head and Neck Symptom Survey. The subscale score was calculated by taking the first non-negative principle component of the 4 items. The scale was scores range from 0 to 10 with 10 representing the worst pain.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Grade 3 or 4 Adverse Events, (Graded Using Common Terminology Criteria for Adverse Events Criteria 4.0)</measure>
    <time_frame>Up to 3 months post-treatment</time_frame>
    <description>Graphical and descriptive statistical summaries will be generated. Mixed-level general linear modeling will be used. All tests of statistical significance will maintain maximum Type I error of 0.05 (p &lt; 0.05). Frequency distributions will summarize the safety outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and Severity of General Systemic Symptoms (Surveys Such as the Neurotoxicity Scale, Profile of Mood States, and Quality of Life Form)</measure>
    <time_frame>Up to 3 months post-treatment</time_frame>
    <description>Pain severity will be correlated with frequency and severity of general systemic symptoms. Graphical and descriptive statistical summaries will be generated. Mixed-level general linear modeling will be used. All tests of statistical significance will maintain maximum Type I error of 0.05 (p &lt; 0.05). Baseline pain scores will be included as a covariate in the analyses of the outcome. The General Symptom Survey is a ten item patient reported outcome measure and outcomes were averaged as there is only one item per symptom category. 0 represented no presence of the symptom with a score of 10 representing the most severe symptom.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">79</enrollment>
  <condition>Malignant Head and Neck Neoplasm</condition>
  <condition>Mucositis</condition>
  <condition>Radiation-Induced Disorder</condition>
  <arm_group>
    <arm_group_label>Arm I Standard of Care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive standard of care consisting of oral health measures, oral rinsing, miracle mouthwash, nonsteroidal anti-inflammatories, and opioid analgesics. Patients also undergo an education session at the beginning of treatment to review foundations of oral care and pain management.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II Standard of Care Plus Gabapentin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive standard of care and undergo an education session as in Arm I. Patients also receive gabapentin PO three times a day throughout chemoradiation treatment (approximately 5-7 weeks) and until mucositis resolves and pain subsides.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Educational Intervention</intervention_name>
    <description>Undergo oral care and pain management education session</description>
    <arm_group_label>Arm I Standard of Care</arm_group_label>
    <arm_group_label>Arm II Standard of Care Plus Gabapentin</arm_group_label>
    <other_name>Education for Intervention</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gabapentin</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm II Standard of Care Plus Gabapentin</arm_group_label>
    <other_name>Gralise</other_name>
    <other_name>Neurontin</other_name>
    <other_name>1-(aminomethyl) cyclohexaneacetic Acid, 60142-96-3,</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pain Therapy</intervention_name>
    <description>Receive usual oral health care</description>
    <arm_group_label>Arm I Standard of Care</arm_group_label>
    <arm_group_label>Arm II Standard of Care Plus Gabapentin</arm_group_label>
    <other_name>Analgesia</other_name>
    <other_name>Pain Control</other_name>
    <other_name>Pain Management</other_name>
    <other_name>Pain</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Quality-of-Life Assessment</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Arm I Standard of Care</arm_group_label>
    <arm_group_label>Arm II Standard of Care Plus Gabapentin</arm_group_label>
    <other_name>Quality of Life Assessment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire Administration</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Arm I Standard of Care</arm_group_label>
    <arm_group_label>Arm II Standard of Care Plus Gabapentin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxycodone/Acetaminophen</intervention_name>
    <description>Analgesia</description>
    <arm_group_label>Arm I Standard of Care</arm_group_label>
    <arm_group_label>Arm II Standard of Care Plus Gabapentin</arm_group_label>
    <other_name>Percocet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydrocodone/Acetaminophen</intervention_name>
    <description>Analgesia</description>
    <arm_group_label>Arm I Standard of Care</arm_group_label>
    <arm_group_label>Arm II Standard of Care Plus Gabapentin</arm_group_label>
    <other_name>Lortab</other_name>
    <other_name>Vicodin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fentanyl</intervention_name>
    <description>Transdermal Analgesia</description>
    <arm_group_label>Arm I Standard of Care</arm_group_label>
    <arm_group_label>Arm II Standard of Care Plus Gabapentin</arm_group_label>
    <other_name>Duragesic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibuprofen</intervention_name>
    <description>NSAID Analgesia</description>
    <arm_group_label>Arm I Standard of Care</arm_group_label>
    <arm_group_label>Arm II Standard of Care Plus Gabapentin</arm_group_label>
    <other_name>Motrin</other_name>
    <other_name>Advil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Magic Mouthwash</intervention_name>
    <description>Oral Solution to treat mucositis</description>
    <arm_group_label>Arm I Standard of Care</arm_group_label>
    <arm_group_label>Arm II Standard of Care Plus Gabapentin</arm_group_label>
    <other_name>Miracle Mouthwash</other_name>
    <other_name>First-Mouthwash BLM</other_name>
    <other_name>First-BXN Mouthwash</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically proven cancer of the head and neck cancer&#xD;
&#xD;
          -  Stage 3 or 4&#xD;
&#xD;
          -  Planned primary or adjuvant chemoradiation therapy&#xD;
&#xD;
          -  Willing and able to provide informed consent&#xD;
&#xD;
          -  English speaking&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Currently on gabapentin&#xD;
&#xD;
          -  Prior non-tolerance of gabapentin&#xD;
&#xD;
          -  History of seizure disorder&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Derek Smith, DDS,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University/Ingram Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vanderbilt University/Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>June 16, 2015</study_first_submitted>
  <study_first_submitted_qc>June 21, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 24, 2015</study_first_posted>
  <results_first_submitted>August 12, 2020</results_first_submitted>
  <results_first_submitted_qc>September 3, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">September 24, 2020</results_first_posted>
  <last_update_submitted>January 28, 2021</last_update_submitted>
  <last_update_submitted_qc>January 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt-Ingram Cancer Center</investigator_affiliation>
    <investigator_full_name>Derek Smith</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Mucositis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Ibuprofen</mesh_term>
    <mesh_term>Acetaminophen, hydrocodone drug combination</mesh_term>
    <mesh_term>Fentanyl</mesh_term>
    <mesh_term>Oxycodone</mesh_term>
    <mesh_term>Hydrocodone</mesh_term>
    <mesh_term>Gabapentin</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>January 23, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/14/NCT02480114/ICF_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 28, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/14/NCT02480114/Prot_SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled at Vanderbilt Medical Center in Nashville, TN from July 2015 to May 2019. 79 participants were recruited and 8 of those withdrew.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Arm II Standard of Care Plus Gabapentin</title>
          <description>Patients receive standard of care and undergo an education session as in Arm I. Patients also receive gabapentin PO three times a day throughout chemoradiation treatment (approximately 5-7 weeks) and until mucositis resolves and pain subsides.&#xD;
Educational Intervention: Undergo oral care and pain management education session&#xD;
Gabapentin: Given PO&#xD;
Pain Therapy: Receive usual oral health care&#xD;
Quality-of-Life Assessment: Ancillary studies&#xD;
Questionnaire Administration: Ancillary studies&#xD;
Oxycodone/Acetaminophen: Analgesia&#xD;
Hydrocodone/Acetaminophen: Analgesia&#xD;
Fentanyl: Transdermal Analgesia&#xD;
Ibuprofen: NSAID Analgesia&#xD;
Magic Mouthwash: Oral Solution to treat mucositis</description>
        </group>
        <group group_id="P2">
          <title>Arm I Standard of Care</title>
          <description>Patients receive standard of care consisting of oral health measures, oral rinsing, miracle mouthwash, nonsteroidal anti-inflammatories, and opioid analgesics. Patients also undergo an education session at the beginning of treatment to review foundations of oral care and pain management.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="38"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Not completing surveys</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Disease progression</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Improper completion of survey</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not eligible</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm I Standard of Care</title>
          <description>Patients receive standard of care consisting of oral health measures, oral rinsing, miracle mouthwash, nonsteroidal anti-inflammatories, and opioid analgesics. Patients also undergo an education session at the beginning of treatment to review foundations of oral care and pain management.&#xD;
Educational Intervention: Undergo oral care and pain management education session&#xD;
Pain Therapy: Receive usual oral health care&#xD;
Quality-of-Life Assessment: Ancillary studies&#xD;
Questionnaire Administration: Ancillary studies&#xD;
Oxycodone/Acetaminophen: Analgesia&#xD;
Hydrocodone/Acetaminophen: Analgesia&#xD;
Fentanyl: Transdermal Analgesia&#xD;
Ibuprofen: NSAID Analgesia&#xD;
Magic Mouthwash: Oral Solution to treat mucositis</description>
        </group>
        <group group_id="B2">
          <title>Arm II Standard of Care Plus Gabapentin</title>
          <description>Patients receive standard of care and undergo an education session as in Arm I. Patients also receive gabapentin PO three times a day throughout chemoradiation treatment (approximately 5-7 weeks) and until mucositis resolves and pain subsides.&#xD;
Educational Intervention: Undergo oral care and pain management education session&#xD;
Gabapentin: Given PO&#xD;
Pain Therapy: Receive usual oral health care&#xD;
Quality-of-Life Assessment: Ancillary studies&#xD;
Questionnaire Administration: Ancillary studies&#xD;
Oxycodone/Acetaminophen: Analgesia&#xD;
Hydrocodone/Acetaminophen: Analgesia&#xD;
Fentanyl: Transdermal Analgesia&#xD;
Ibuprofen: NSAID Analgesia&#xD;
Magic Mouthwash: Oral Solution to treat mucositis</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="38"/>
            <count group_id="B2" value="41"/>
            <count group_id="B3" value="79"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="66"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.5" lower_limit="54.75" upper_limit="66.25"/>
                    <measurement group_id="B2" value="61" lower_limit="52" upper_limit="66"/>
                    <measurement group_id="B3" value="61" lower_limit="53" upper_limit="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="72"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Pain Associated With Radiation-induced Mucositis, (Pain Subscale of the Vanderbilt Head and Neck Symptom Survey (VHNSS))</title>
        <description>The pain subscale is composed of 4 items of the Vanderbilt Head and Neck Symptom Survey. The subscale score was calculated by taking the first non-negative principle component of the 4 items. The scale was scores range from 0 to 10 with 10 representing the worst pain.</description>
        <time_frame>Up to 3 months post-treatment</time_frame>
        <population>Longitudinal analysis was completed including all patients in both arms of the study. Although some patients stopped filling out surveys part way through the study and therefore are not marked as 'complete' in the patient flow section, the data they did provide was still used for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I Standard of Care</title>
            <description>Patients receive standard of care consisting of oral health measures, oral rinsing, miracle mouthwash, nonsteroidal anti-inflammatories, and opioid analgesics. Patients also undergo an education session at the beginning of treatment to review foundations of oral care and pain management.&#xD;
Educational Intervention: Undergo oral care and pain management education session&#xD;
Pain Therapy: Receive usual oral health care&#xD;
Quality-of-Life Assessment: Ancillary studies&#xD;
Questionnaire Administration: Ancillary studies&#xD;
Oxycodone/Acetaminophen: Analgesia&#xD;
Hydrocodone/Acetaminophen: Analgesia&#xD;
Fentanyl: Transdermal Analgesia&#xD;
Ibuprofen: NSAID Analgesia&#xD;
Magic Mouthwash: Oral Solution to treat mucositis</description>
          </group>
          <group group_id="O2">
            <title>Arm II Standard of Care Plus Gabapentin</title>
            <description>Patients receive standard of care and undergo an education session as in Arm I. Patients also receive gabapentin PO three times a day throughout chemoradiation treatment (approximately 5-7 weeks) and until mucositis resolves and pain subsides.&#xD;
Educational Intervention: Undergo oral care and pain management education session&#xD;
Gabapentin: Given PO&#xD;
Pain Therapy: Receive usual oral health care&#xD;
Quality-of-Life Assessment: Ancillary studies&#xD;
Questionnaire Administration: Ancillary studies&#xD;
Oxycodone/Acetaminophen: Analgesia&#xD;
Hydrocodone/Acetaminophen: Analgesia&#xD;
Fentanyl: Transdermal Analgesia&#xD;
Ibuprofen: NSAID Analgesia&#xD;
Magic Mouthwash: Oral Solution to treat mucositis</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Pain Associated With Radiation-induced Mucositis, (Pain Subscale of the Vanderbilt Head and Neck Symptom Survey (VHNSS))</title>
          <description>The pain subscale is composed of 4 items of the Vanderbilt Head and Neck Symptom Survey. The subscale score was calculated by taking the first non-negative principle component of the 4 items. The scale was scores range from 0 to 10 with 10 representing the worst pain.</description>
          <population>Longitudinal analysis was completed including all patients in both arms of the study. Although some patients stopped filling out surveys part way through the study and therefore are not marked as 'complete' in the patient flow section, the data they did provide was still used for analysis.</population>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.26" lower_limit="3.98" upper_limit="5.16"/>
                    <measurement group_id="O2" value="3.68" lower_limit="2.04" upper_limit="3.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.004</p_value>
            <method>Proportional Odds Regression</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.549</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.364</ci_lower_limit>
            <ci_upper_limit>0.827</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Grade 3 or 4 Adverse Events, (Graded Using Common Terminology Criteria for Adverse Events Criteria 4.0)</title>
        <description>Graphical and descriptive statistical summaries will be generated. Mixed-level general linear modeling will be used. All tests of statistical significance will maintain maximum Type I error of 0.05 (p &lt; 0.05). Frequency distributions will summarize the safety outcome.</description>
        <time_frame>Up to 3 months post-treatment</time_frame>
        <population>All patients in both arms were analyzed. Although some patients stopped filling out surveys part way through the study and therefore are not marked as 'complete' in the patient flow section, the data they did provide was still used for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I Standard of Care</title>
            <description>Patients receive standard of care consisting of oral health measures, oral rinsing, miracle mouthwash, nonsteroidal anti-inflammatories, and opioid analgesics. Patients also undergo an education session at the beginning of treatment to review foundations of oral care and pain management.&#xD;
Educational Intervention: Undergo oral care and pain management education session&#xD;
Pain Therapy: Receive usual oral health care&#xD;
Quality-of-Life Assessment: Ancillary studies&#xD;
Questionnaire Administration: Ancillary studies&#xD;
Oxycodone/Acetaminophen: Analgesia&#xD;
Hydrocodone/Acetaminophen: Analgesia&#xD;
Fentanyl: Transdermal Analgesia&#xD;
Ibuprofen: NSAID Analgesia&#xD;
Magic Mouthwash: Oral Solution to treat mucositis</description>
          </group>
          <group group_id="O2">
            <title>Arm II Standard of Care Plus Gabapentin</title>
            <description>Patients receive standard of care and undergo an education session as in Arm I. Patients also receive gabapentin PO three times a day throughout chemoradiation treatment (approximately 5-7 weeks) and until mucositis resolves and pain subsides.&#xD;
Educational Intervention: Undergo oral care and pain management education session&#xD;
Gabapentin: Given PO&#xD;
Pain Therapy: Receive usual oral health care&#xD;
Quality-of-Life Assessment: Ancillary studies&#xD;
Questionnaire Administration: Ancillary studies&#xD;
Oxycodone/Acetaminophen: Analgesia&#xD;
Hydrocodone/Acetaminophen: Analgesia&#xD;
Fentanyl: Transdermal Analgesia&#xD;
Ibuprofen: NSAID Analgesia&#xD;
Magic Mouthwash: Oral Solution to treat mucositis</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Grade 3 or 4 Adverse Events, (Graded Using Common Terminology Criteria for Adverse Events Criteria 4.0)</title>
          <description>Graphical and descriptive statistical summaries will be generated. Mixed-level general linear modeling will be used. All tests of statistical significance will maintain maximum Type I error of 0.05 (p &lt; 0.05). Frequency distributions will summarize the safety outcome.</description>
          <population>All patients in both arms were analyzed. Although some patients stopped filling out surveys part way through the study and therefore are not marked as 'complete' in the patient flow section, the data they did provide was still used for analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>1</p_value>
            <method>Fisher Exact</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency and Severity of General Systemic Symptoms (Surveys Such as the Neurotoxicity Scale, Profile of Mood States, and Quality of Life Form)</title>
        <description>Pain severity will be correlated with frequency and severity of general systemic symptoms. Graphical and descriptive statistical summaries will be generated. Mixed-level general linear modeling will be used. All tests of statistical significance will maintain maximum Type I error of 0.05 (p &lt; 0.05). Baseline pain scores will be included as a covariate in the analyses of the outcome. The General Symptom Survey is a ten item patient reported outcome measure and outcomes were averaged as there is only one item per symptom category. 0 represented no presence of the symptom with a score of 10 representing the most severe symptom.</description>
        <time_frame>Up to 3 months post-treatment</time_frame>
        <population>Although some patients stopped filling out surveys part way through the study and therefore are not marked as 'complete' in the patient flow section, the data they did provide was still used for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I Standard of Care</title>
            <description>Patients receive standard of care consisting of oral health measures, oral rinsing, miracle mouthwash, nonsteroidal anti-inflammatories, and opioid analgesics. Patients also undergo an education session at the beginning of treatment to review foundations of oral care and pain management.&#xD;
Educational Intervention: Undergo oral care and pain management education session&#xD;
Pain Therapy: Receive usual oral health care&#xD;
Quality-of-Life Assessment: Ancillary studies&#xD;
Questionnaire Administration: Ancillary studies&#xD;
Oxycodone/Acetaminophen: Analgesia&#xD;
Hydrocodone/Acetaminophen: Analgesia&#xD;
Fentanyl: Transdermal Analgesia&#xD;
Ibuprofen: NSAID Analgesia&#xD;
Magic Mouthwash: Oral Solution to treat mucositis</description>
          </group>
          <group group_id="O2">
            <title>Arm II Standard of Care Plus Gabapentin</title>
            <description>Patients receive standard of care and undergo an education session as in Arm I. Patients also receive gabapentin PO three times a day throughout chemoradiation treatment (approximately 5-7 weeks) and until mucositis resolves and pain subsides.&#xD;
Educational Intervention: Undergo oral care and pain management education session&#xD;
Gabapentin: Given PO&#xD;
Pain Therapy: Receive usual oral health care&#xD;
Quality-of-Life Assessment: Ancillary studies&#xD;
Questionnaire Administration: Ancillary studies&#xD;
Oxycodone/Acetaminophen: Analgesia&#xD;
Hydrocodone/Acetaminophen: Analgesia&#xD;
Fentanyl: Transdermal Analgesia&#xD;
Ibuprofen: NSAID Analgesia&#xD;
Magic Mouthwash: Oral Solution to treat mucositis</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency and Severity of General Systemic Symptoms (Surveys Such as the Neurotoxicity Scale, Profile of Mood States, and Quality of Life Form)</title>
          <description>Pain severity will be correlated with frequency and severity of general systemic symptoms. Graphical and descriptive statistical summaries will be generated. Mixed-level general linear modeling will be used. All tests of statistical significance will maintain maximum Type I error of 0.05 (p &lt; 0.05). Baseline pain scores will be included as a covariate in the analyses of the outcome. The General Symptom Survey is a ten item patient reported outcome measure and outcomes were averaged as there is only one item per symptom category. 0 represented no presence of the symptom with a score of 10 representing the most severe symptom.</description>
          <population>Although some patients stopped filling out surveys part way through the study and therefore are not marked as 'complete' in the patient flow section, the data they did provide was still used for analysis.</population>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.91" lower_limit="0.73" upper_limit="3.56"/>
                    <measurement group_id="O2" value="1.23" lower_limit="0.45" upper_limit="2.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Proportional Odds Regression</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.371</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.244</ci_lower_limit>
            <ci_upper_limit>0.597</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Approximately 3 months after completion of treatment</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Arm I Standard of Care</title>
          <description>Patients receive standard of care consisting of oral health measures, oral rinsing, miracle mouthwash, nonsteroidal anti-inflammatories, and opioid analgesics. Patients also undergo an education session at the beginning of treatment to review foundations of oral care and pain management.&#xD;
Educational Intervention: Undergo oral care and pain management education session&#xD;
Pain Therapy: Receive usual oral health care&#xD;
Quality-of-Life Assessment: Ancillary studies&#xD;
Questionnaire Administration: Ancillary studies&#xD;
Oxycodone/Acetaminophen: Analgesia&#xD;
Hydrocodone/Acetaminophen: Analgesia&#xD;
Fentanyl: Transdermal Analgesia&#xD;
Ibuprofen: NSAID Analgesia&#xD;
Magic Mouthwash: Oral Solution to treat mucositis</description>
        </group>
        <group group_id="E2">
          <title>Arm II Standard of Care Plus Gabapentin</title>
          <description>Patients receive standard of care and undergo an education session as in Arm I. Patients also receive gabapentin PO three times a day throughout chemoradiation treatment (approximately 5-7 weeks) and until mucositis resolves and pain subsides.&#xD;
Educational Intervention: Undergo oral care and pain management education session&#xD;
Gabapentin: Given PO&#xD;
Pain Therapy: Receive usual oral health care&#xD;
Quality-of-Life Assessment: Ancillary studies&#xD;
Questionnaire Administration: Ancillary studies&#xD;
Oxycodone/Acetaminophen: Analgesia&#xD;
Hydrocodone/Acetaminophen: Analgesia&#xD;
Fentanyl: Transdermal Analgesia&#xD;
Ibuprofen: NSAID Analgesia&#xD;
Magic Mouthwash: Oral Solution to treat mucositis</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE criteria 4.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Derek Smith, DDS, PhD</name_or_title>
      <organization>Vanderbilt University Medical Center</organization>
      <phone>6159367423</phone>
      <email>derek.k.smith@vumc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

